1. Dissolution testing of immediate-release solid oral dosage forms. Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD; 1997.
2. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD; 2017.
3. Abend A, Heimbach T, Cohen M, Kesisoglou F, Pipen X, Suarez-Sharp S. Dissolution and translational modeling strategies enabling patient-centric drug product development: the M-CERSI workshop summary report. AAPS J. 2018;20:60.
https://doi.org/10.1208/s12248-018-0213-x
.
4. Marroum PJ. Clinically relevant dissolution methods and specifications. Am Pharm Rev. 2012;15(1):36–41.
5. Suarez S, Marroum P, Hughes M. In: Shargel L, Yu A, editors. Chapter 15, Biopharmaceutic considerations in drug product design and in vitro drug product performance, Applied biopharmaceutics and pharmacokinetics. 7th ed: McGraw-Hill Education; 2016.